Neratinib augments the lethality of [regorafenib + sildenafil]
- PMID: 30203445
- PMCID: PMC6322207
- DOI: 10.1002/jcp.27276
Neratinib augments the lethality of [regorafenib + sildenafil]
Abstract
Regorafenib is approved for the treatment of colorectal cancer and hepatocellular carcinoma. In the trial NCT02466802, we have discovered that regorafenib can be safely combined with the phosphodiesterase 5 inhibitor sildenafil in advanced solid tumor patients. The present studies determined whether the approved ERBB1/2/4 and RAS downregulating drug neratinib, could enhance the lethality of [regorafenib + sildenafil]. Neratinib enhanced [regorafenib + sildenafil] lethality in a greater than additive fashion in colon cancer cells. The drug combination reduced the expression of mutant K-RAS and of multiple histone deacetylase (HDAC) proteins that required autophagosome formation. It caused green fluorescent protein or red fluorescent protein-tagged forms of K-RAS V12 to localize into large intracellular vesicles. Compared with [regorafenib + sildenafil], the three-drug combination caused greater and more prolonged activation of the ATM-AMPK-ULK-1 pathway and caused a greater suppression and prolonged inactivation of mammalian target of rapamycin, AKT, and p70 S6K. Approximately 70% of enhanced lethality caused by neratinib required ataxia-telangiectasia-mutated (ATM)-AMP-dependent protein kinase (AMPK) signaling whereas knockdown of Beclin1, ATG5, FADD, and CD95 completely prevented the elevated killing effect. Exposure of cells to [regorafenib + sildenafil] reduced the expression of the checkpoint immunotherapy biomarkers programmed death-ligand 1, ornithine decarboxylase, and indoleamine 2,3-dioxygenase-1 and increased the expression of major histocompatibility complex A (MHCA), which also required autophagosome formation. Knockdown of specific HDAC proteins recapitulated the effects observed using chemical agents. In vivo, using mouse cancer models, neratinib significantly enhanced the antitumor efficacy of [regorafenib + sildenafil]. Our data support performing a new three drug Phase I trial combining regorafenib, sildenafil, and neratinib.
Keywords: DNA damage; HDAC; autophagy.
© 2018 Wiley Periodicals, Inc.
Conflict of interest statement
There are no conflicts of interest to report.
Figures











Similar articles
-
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20. Cancer Biol Ther. 2019. PMID: 30571927 Free PMC article.
-
Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.Cancer Biol Ther. 2019;20(2):157-168. doi: 10.1080/15384047.2018.1507665. Epub 2018 Sep 5. Cancer Biol Ther. 2019. PMID: 30183517 Free PMC article.
-
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].Oncotarget. 2017 Feb 21;8(8):13464-13475. doi: 10.18632/oncotarget.14562. Oncotarget. 2017. PMID: 28088782 Free PMC article.
-
Molecular insight of regorafenib treatment for colorectal cancer.Cancer Treat Rev. 2019 Dec;81:101912. doi: 10.1016/j.ctrv.2019.101912. Epub 2019 Oct 28. Cancer Treat Rev. 2019. PMID: 31715423 Free PMC article. Review.
-
Regorafenib in the treatment of metastatic colorectal cancer.Future Oncol. 2018 Sep;14(22):2239-2246. doi: 10.2217/fon-2017-0512. Epub 2018 Mar 23. Future Oncol. 2018. PMID: 29569472 Review.
Cited by
-
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.Front Oncol. 2019 Jul 18;9:650. doi: 10.3389/fonc.2019.00650. eCollection 2019. Front Oncol. 2019. PMID: 31380285 Free PMC article.
-
Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43.Aging (Albany NY). 2021 Jul 12;13(13):17097-17117. doi: 10.18632/aging.203297. Epub 2021 Jul 12. Aging (Albany NY). 2021. PMID: 34252884 Free PMC article.
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.Pigment Cell Melanoma Res. 2022 Jan;35(1):66-77. doi: 10.1111/pcmr.13014. Epub 2021 Sep 4. Pigment Cell Melanoma Res. 2022. PMID: 34482636 Free PMC article.
-
Fingolimod Augments Monomethylfumarate Killing of GBM Cells.Front Oncol. 2020 Jan 28;10:22. doi: 10.3389/fonc.2020.00022. eCollection 2020. Front Oncol. 2020. PMID: 32047722 Free PMC article.
-
Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health.Front Endocrinol (Lausanne). 2024 Sep 17;15:1461642. doi: 10.3389/fendo.2024.1461642. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39355618 Free PMC article. Review.
References
-
- Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. (2016b) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. 7:12975–96. - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous